- Home
- FENC vs TLSA Comparison
FENC vs TLSA Comparison
Compare FENC & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- TLSA
- Stock Information
- Founded
- FENC 1996
- TLSA 2013
- Country
- FENC United States
- TLSA United Kingdom
- Employees
- FENC N/A
- TLSA N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- TLSA Health Care
- Exchange
- FENC Nasdaq
- TLSA Nasdaq
- Market Cap
- FENC 225.4M
- TLSA 187.0M
- IPO Year
- FENC 2001
- TLSA 2000
- Fundamental
- Price
- FENC $8.94
- TLSA $1.79
- Analyst Decision
- FENC Strong Buy
- TLSA
- Analyst Count
- FENC 2
- TLSA 0
- Target Price
- FENC $13.50
- TLSA N/A
- AVG Volume (30 Days)
- FENC 67.1K
- TLSA 381.3K
- Earning Date
- FENC 08-14-2025
- TLSA 05-06-2025
- Dividend Yield
- FENC N/A
- TLSA N/A
- EPS Growth
- FENC N/A
- TLSA N/A
- EPS
- FENC N/A
- TLSA N/A
- Revenue
- FENC $33,302,000.00
- TLSA N/A
- Revenue This Year
- FENC $0.96
- TLSA N/A
- Revenue Next Year
- FENC $51.71
- TLSA N/A
- P/E Ratio
- FENC N/A
- TLSA N/A
- Revenue Growth
- FENC N/A
- TLSA N/A
- 52 Week Low
- FENC $3.96
- TLSA $0.63
- 52 Week High
- FENC $9.42
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- FENC 56.61
- TLSA 43.74
- Support Level
- FENC $7.57
- TLSA $1.75
- Resistance Level
- FENC $9.11
- TLSA $2.00
- Average True Range (ATR)
- FENC 0.53
- TLSA 0.14
- MACD
- FENC 0.06
- TLSA -0.04
- Stochastic Oscillator
- FENC 75.56
- TLSA 11.46
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.